Link to this page
The Drug-Drug Interactions Ontology
Last uploaded:
February 11, 2016
Jump to:
| Preferred Name | alogliptin | |
| Synonyms |
alogliptinum C18H21N5O2 alogliptina alogliptine 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile alogliptin |
|
| ID |
http://purl.obolibrary.org/obo/CHEBI_72323 |
|
| AHFScode |
68:20.05
|
|
| ATCCode |
A10BH04
|
|
| binds |
http://purl.obolibrary.org/obo/dinto_2272 |
|
| CASRN |
850649-61-5
|
|
| DBBrand |
nesina
|
|
| DBSalt |
alogliptin benzoate
|
|
| DBSynonym |
syr-322
|
|
| Definition |
A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes. Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
|
|
| has pharmacological target | ||
| has role | ||
| InChI |
InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
|
|
| InChIKey |
InChIKey=ZSBOMTDTBDDKMP-OAHLLOKOSA-N
|
|
| inhibits | ||
| is metabolised by | ||
| is substrate of | ||
| label |
alogliptin
|
|
| prefixIRI |
obo2:CHEBI_72323
|
|
| prefLabel |
alogliptin
|
|
| SMILES |
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
|
|
| Synonym |
alogliptinum C18H21N5O2 alogliptina alogliptine 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}methyl)benzonitrile 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile alogliptin
|
|
| xref |
CiteXplore:21397040 CiteXplore:23289982 CiteXplore:22106975 CiteXplore:22296609 CiteXplore:22419732 CiteXplore:23220949 CiteXplore:20040339 CiteXplore:21682833 RxList:http://www.rxlist.com/nesina-drug/patient-images-side-effects.htm Drugs.com:http://www.drugs.com/mtm/alogliptin.html CiteXplore:21558879 CiteXplore:21806314 CiteXplore:22249941 CiteXplore:23298374 Patent:EP1970063 ChEMBL:477721 CiteXplore:22237690 Patent:WO2010072680 Reaxys:10587993 ChEBI:72323 CiteXplore:22162539 CiteXplore:22512582 CiteXplore:22583697 Patent:US2007066635 National Drug Code Directory:64764-250-30 CiteXplore:21733058 Patent:US2009275750 CiteXplore:22832924 Patent:WO2008028914 CiteXplore:21595275 CASRN:850649-61-5 CiteXplore:21431099 CiteXplore:21205126 Wikipedia:http://en.wikipedia.org/wiki/Alogliptin CiteXplore:22651127 CiteXplore:22429011 Wikipedia:Alogliptin Patent:WO2009022009 CiteXplore:21595274
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping